Epigenomics of ovarian cancer and its chemoprevention
Ovarian cancer is a major cause of death among gynecological cancers and its etiology is still unclear. Currently, the two principle obstacles in treating this life threatening disease are lack of effective biomarkers for early detection and drug resistance after initial chemotherapy. Similar to oth...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-10-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fgene.2011.00067/full |
| _version_ | 1811339221201321984 |
|---|---|
| author | Huaping eChen Tabitha M. Hardy Trygve eTollefsbol |
| author_facet | Huaping eChen Tabitha M. Hardy Trygve eTollefsbol |
| author_sort | Huaping eChen |
| collection | DOAJ |
| description | Ovarian cancer is a major cause of death among gynecological cancers and its etiology is still unclear. Currently, the two principle obstacles in treating this life threatening disease are lack of effective biomarkers for early detection and drug resistance after initial chemotherapy. Similar to other cancers, the initiation and development of ovarian cancer is characterized by disruption of oncogenes and tumor suppressor genes by both genetic and epigenetic mechanisms. While it is well known that it is challenging to treat ovarian cancer through a genetic strategy due in part to its heterogeneity, the reversibility of epigenetic mechanisms involved in ovarian cancer opens exciting new avenues for treatment. The epigenomics of ovarian cancer has therefore become a rapidly expanding field leading to intense investigation. In this analysis, we will evaluate the current status of epigenomics of ovarian cancer and will include epigenetic mechanisms involved in ovarian cancer development. The role of DNA methylation, histone modifications, noncoding microRNA, development of biomarkers, the epigenetic basis for drug resistance and improved chemotherapy for ovarian cancer will also be assessed. In addition, the potential use of natural compounds as epigenetic modulators in chemotherapy shows promise in moving to the forefront of ovarian cancer treatment strategies. |
| first_indexed | 2024-04-13T18:23:03Z |
| format | Article |
| id | doaj.art-f88479e8f4ba4101ade741bda12b8ab6 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-13T18:23:03Z |
| publishDate | 2011-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-f88479e8f4ba4101ade741bda12b8ab62022-12-22T02:35:23ZengFrontiers Media S.A.Frontiers in Genetics1664-80212011-10-01210.3389/fgene.2011.0006713918Epigenomics of ovarian cancer and its chemopreventionHuaping eChen0Tabitha M. Hardy1Trygve eTollefsbol2University of Alabama at BirminghamUniversity of Alabama at BirminghamUniversity of Alabama at BirminghamOvarian cancer is a major cause of death among gynecological cancers and its etiology is still unclear. Currently, the two principle obstacles in treating this life threatening disease are lack of effective biomarkers for early detection and drug resistance after initial chemotherapy. Similar to other cancers, the initiation and development of ovarian cancer is characterized by disruption of oncogenes and tumor suppressor genes by both genetic and epigenetic mechanisms. While it is well known that it is challenging to treat ovarian cancer through a genetic strategy due in part to its heterogeneity, the reversibility of epigenetic mechanisms involved in ovarian cancer opens exciting new avenues for treatment. The epigenomics of ovarian cancer has therefore become a rapidly expanding field leading to intense investigation. In this analysis, we will evaluate the current status of epigenomics of ovarian cancer and will include epigenetic mechanisms involved in ovarian cancer development. The role of DNA methylation, histone modifications, noncoding microRNA, development of biomarkers, the epigenetic basis for drug resistance and improved chemotherapy for ovarian cancer will also be assessed. In addition, the potential use of natural compounds as epigenetic modulators in chemotherapy shows promise in moving to the forefront of ovarian cancer treatment strategies.http://journal.frontiersin.org/Journal/10.3389/fgene.2011.00067/fullChemopreventionEpigenomicsbiomarkersovarian cancer |
| spellingShingle | Huaping eChen Tabitha M. Hardy Trygve eTollefsbol Epigenomics of ovarian cancer and its chemoprevention Frontiers in Genetics Chemoprevention Epigenomics biomarkers ovarian cancer |
| title | Epigenomics of ovarian cancer and its chemoprevention |
| title_full | Epigenomics of ovarian cancer and its chemoprevention |
| title_fullStr | Epigenomics of ovarian cancer and its chemoprevention |
| title_full_unstemmed | Epigenomics of ovarian cancer and its chemoprevention |
| title_short | Epigenomics of ovarian cancer and its chemoprevention |
| title_sort | epigenomics of ovarian cancer and its chemoprevention |
| topic | Chemoprevention Epigenomics biomarkers ovarian cancer |
| url | http://journal.frontiersin.org/Journal/10.3389/fgene.2011.00067/full |
| work_keys_str_mv | AT huapingechen epigenomicsofovariancanceranditschemoprevention AT tabithamhardy epigenomicsofovariancanceranditschemoprevention AT trygveetollefsbol epigenomicsofovariancanceranditschemoprevention |